1. Home
  2. FCBC vs OMER Comparison

FCBC vs OMER Comparison

Compare FCBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Community Bankshares Inc. (VA)

FCBC

First Community Bankshares Inc. (VA)

HOLD

Current Price

$41.00

Market Cap

753.5M

Sector

Finance

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.73

Market Cap

788.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCBC
OMER
Founded
1874
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.5M
788.4M
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
FCBC
OMER
Price
$41.00
$10.73
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
72.0K
703.2K
Earning Date
04-21-2026
03-12-2026
Dividend Yield
5.64%
N/A
EPS Growth
N/A
N/A
EPS
2.65
N/A
Revenue
N/A
$29,868,000.00
Revenue This Year
$12.28
N/A
Revenue Next Year
$2.55
N/A
P/E Ratio
$15.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.21
$2.95
52 Week High
$42.15
$17.65

Technical Indicators

Market Signals
Indicator
FCBC
OMER
Relative Strength Index (RSI) 59.29 38.91
Support Level $38.60 $10.55
Resistance Level $41.56 $11.93
Average True Range (ATR) 1.08 0.47
MACD -0.08 -0.06
Stochastic Oscillator 85.28 9.71

Price Performance

Historical Comparison
FCBC
OMER

About FCBC First Community Bankshares Inc. (VA)

First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: